Martin R Wilkins

List of Publications by Year
in descending order

185 papers	13,625 citations	23567 58 h-index	22832 112 g-index
207 all docs	207 docs citations	207 times ranked	12406 citing authors

#	Article	IF	Citations
1	Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50.	2.8	1,467
2	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 319-329.	27.0	1,144
3	Mechanisms of disease: pulmonary arterial hypertension. Nature Reviews Cardiology, 2011, 8, 443-455.	13.7	605
4	Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension. Circulation, 2001, 104, 424-428.	1.6	458
5	Basic Science of Pulmonary Arterial Hypertension for Clinicians. Circulation, 2010, 121, 2045-2066.	1.6	440
6	Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1292-1297.	5.6	345
7	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	27.8	338
8	Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 105-113.	5.6	316
9	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
10	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal, 2015, 45, 1293-1302.	6.7	247
11	Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension. Circulation, 2003, 107, 3230-3235.	1.6	233
12	Histone Deacetylation Inhibition in Pulmonary Hypertension. Circulation, 2012, 126, 455-467.	1.6	222
13	Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3020-3030.	1.6	208
14	Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2011, 58, 300-309.	2.8	208
15	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	12.4	206
16	Deep-learning cardiac motion analysis for human survival prediction. Nature Machine Intelligence, 2019, 1, 95-104.	16.0	179
17	Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. Radiology, 2017, 283, 381-390.	7.3	161
18	Neutrophil Extracellular Traps Promote Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2078-2087.	2.4	158

#	Article	IF	Citations
19	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart, 2011, 97, 1054-1060.	2.9	154
20	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation, 2017, 135, 460-475.	1.6	154
21	Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 294-302.	5.6	153
22	Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Human Mutation, 2011, 32, 1385-1389.	2.5	152
23	Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908.	6.7	142
24	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	6.7	136
25	Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 534-541.	5.6	134
26	Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension. Circulation, 2008, 118, 1486-1495.	1.6	133
27	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. European Respiratory Journal, 2008, 32, 198-209.	6.7	129
28	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
29	Characterization of High-Altitude Pulmonary Hypertension in the Kyrgyz. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1396-1402.	5.6	115
30	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature, 2015, 524, 356-360.	27.8	113
31	Simvastatin as a Treatment for Pulmonary Hypertension Trial. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1106-1113.	5.6	112
32	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
33	Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension. Circulation, 2010, 122, 2058-2067.	1.6	109
34	Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease. Circulation, 2015, 131, 582-590.	1.6	108
35	Heterogeneity in Lung ¹⁸ FDG Uptake in Pulmonary Arterial Hypertension. Circulation, 2013, 128, 1214-1224.	1.6	107
36	Beneficial Effects of Phosphodiesterase 5 Inhibition in Pulmonary Hypertension Are Influenced by Natriuretic Peptide Activity. Circulation, 2003, 107, 234-237.	1.6	102

#	Article	IF	Citations
37	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	10.7	99
38	A population-based phenome-wide association study of cardiac and aortic structure and function. Nature Medicine, 2020, 26, 1654-1662.	30.7	98
39	Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. European Respiratory Journal, 2011, 38, 1453-1460.	6.7	97
40	Iron Homeostasis and Pulmonary Hypertension. Circulation Research, 2015, 116, 1680-1690.	4.5	97
41	Genetic Determination of Cardiac Mass in Normotensive Rats. Hypertension, 1999, 33, 949-953.	2.7	93
42	Differences in Ventilatory Inefficiency Between Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Chest, 2011, 140, 1284-1291.	0.8	93
43	Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis. Clinical Science, 1986, 71, 157-160.	4.3	88
44	Genetic Association of the Serotonin Transporter in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 793-797.	5.6	88
45	NPR-Aâ€“Deficient Mice Show Increased Susceptibility to Hypoxia-Induced Pulmonary Hypertension. Circulation, 1999, 99, 605-607.	1.6	86
46	Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax, 2005, 60, 683-687.	5.6	82
47	Therapeutic targets in pulmonary arterial hypertension. , 2009, 121, 69-88.		80
48	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
49	Intravenous Iron Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension and Iron Deficiency. Pulmonary Circulation, 2015, 5, 466-472.	1.7	79
50	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.8	79
51	Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia. Circulation Research, 2012, 110, 1423-1434.	4.5	77
52	cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L103-L115.	2.9	74
53	Pulmonary hypertension: the science behind the disease spectrum. European Respiratory Review, 2012, 21, 19-26.	7.1	72
54	Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat.. Journal of Clinical Investigation, 1993, 92, 2702-2712.	8.2	72

#	Article	IF	Citations
55	Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight, 2019, 4, .	5.0	69
56	Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6465-6469.	7.1	64
57	Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1770-1780.	1.6	63
58	Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. British Journal of Pharmacology, 1998, 124, 1455-1462.	5.4	62
59	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	3.6	62
60	Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 224-239.	5.6	60
61	Responsiveness to betaâ€adrenergic receptor stimulation: the effects of age are cardioselective.. British Journal of Clinical Pharmacology, 1982, 14, 821-826.	2.4	59
62	Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 861-869.	5.6	59
63	Atorvastatin in Pulmonary Arterial Hypertension (APATH) study. European Respiratory Journal, 2012, 40, 67-74.	6.7	53
64	Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics, 2006, 6, 2286-2294.	2.2	52
65	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nature Communications, 2020, 11, 1185.	12.8	52
66	Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L981-L987.	2.9	50
67	Simvastatin and sildenafil combine to attenuate pulmonary hypertension. European Respiratory Journal, 2009, 34, 948-957.	6.7	49
68	Ranitidine and cimetidine; drug interactions with single dose and steadyâ€state nifedipine administration.. British Journal of Clinical Pharmacology, 1987, 23, 311-315.	2.4	48
69	Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.. Journal of Clinical Investigation, 1990, 85, 1274-1279.	8.2	47
70	Inhibition of nitric oxide synthesis in vascular smooth muscle by retinoids. British Journal of Pharmacology, 1994, 113, 1448-1454.	5.4	46
71	Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. British Journal of Pharmacology, 1996, 119, 1217-1222.	5.4	45
72	miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. Biochemical Journal, 2014, 462, 103-112.	3.7	45

#	Article	IF	Citations
73	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	5.6	45
74	Induction of nitric oxide synthase in cultured vascular smooth muscle cells: the role of cyclic AMP. British Journal of Pharmacology, 1994, 112, 396-402.	5.4	44
75	Renal response to candoxatrilat in patients with heart failure. Journal of the American College of Cardiology, 1995, 25, 1273-1281.	2.8	43
76	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine, 2021, 13, 80.	8.2	43
77	Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L1359-L1369.	2.9	38
78	Stroke affecting young men after alcoholic binges.. BMJ: British Medical Journal, 1985, 291, 1342-1342.	2.3	37
79	Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. , 2016, 164, 195-203.		37
80	CLIC4/Arf6 Pathway. Circulation Research, 2019, 124, 52-65.	4.5	36
81	The natriuretic peptide family: turning hormones into drugs. Journal of Endocrinology, 1993, 137, 347-359.	2.6	35
82	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111.	5.6	35
83	Short-Term Hemodynamic Effects ofÂApelin in Patients With PulmonaryÂArterial Hypertension. JACC Basic To Translational Science, 2018, 3, 176-186.	4.1	34
84	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax, 2019, 74, 380-389.	5.6	34
85	Supplementation of Iron in Pulmonary Hypertension: Rationale and Design of a Phase II Clinical Trial in Idiopathic Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 100-107.	1.7	32
86	Right Ventricular Hypertrophy Secondary to Pulmonary Hypertension Is Linked to Rat Chromosome 17. Circulation, 2001, 103, 442-447.	1.6	31
87	The ADAMTS13â€“VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801805.	6.7	31
88	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. European Respiratory Journal, 2019, 53, 1801429.	6.7	31
89	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	6.7	31
90	Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clinical Science, 2002, 102, 253-268.	4.3	30

#	Article	IF	Citations
91	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 2021, 69, 103444.	6.1	30
92	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
93	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. Annals of the American Thoracic Society, 2021, 18, 981-988.	3.2	28
94	Recent advances in pulmonary arterial hypertension. F1000Research, 2018, 7, 1128.	1.6	27
95	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	6.7	26
96	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2003201.	6.7	25
97	Î±1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders. Circulation: Cardiovascular Genetics, 2014, 7, 920-929.	5.1	23
98	Fractal Analysis of Right Ventricular Trabeculae in Pulmonary Hypertension. Radiology, 2018, 288, 386-395.	7.3	23
99	Behcet's disease presenting as benign intracranial hypertension.. Postgraduate Medical Journal, 1986, 62, 39-41.	1.8	22
100	Response to Pulmonary Arterial Hypertension Drug Therapies in Patients with Pulmonary Arterial Hypertension and Cardiovascular Risk Factors. Pulmonary Circulation, 2014, 4, 669-678.	1.7	21
101	Pulmonary arterial hypertension â€“ progress in understanding the disease and prioritizing strategies for drug development. Journal of Internal Medicine, 2017, 282, 129-141.	6.0	21
102	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	12.8	21
103	Adrenomedullin activity in chronically hypoxic rat lungs. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 271, H622-H629.	3.2	20
104	Hypoxiaâ€induced pulmonary hypertensionâ€”Utilizing experiments of nature. British Journal of Pharmacology, 2021, 178, 121-131.	5.4	20
105	William Withering and digitalis, 1785 to 1985.. BMJ: British Medical Journal, 1985, 290, 7-8.	2.3	19
106	Natriuretic peptide receptors and the heart. British Heart Journal, 2002, 87, 314-315.	2.1	19
107	What do we want from proteomics in the detection and avoidance of adverse drug reactions. Toxicology Letters, 2002, 127, 245-249.	0.8	19
108	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	5.6	19

#	Article	IF	Citations
109	Effect of lower body positive pressure on blood pressure, plasma atrial natriuretic factor concentration, and sodium and water excretion in healthy volunteers and cardiac transplant recipients. Cardiovascular Research, 1988, 22, 231-235.	3.8	18
110	Nitric oxide, phosphodiesterase inhibition, and adaption to hypoxic conditions. Lancet, The, 2002, 359, 1539-1540.	13.7	18
111	Effects of Tetrahydrobiopterin Oral Treatment in Hypoxiaâ€Induced Pulmonary Hypertension in Rat. Pulmonary Circulation, 2014, 4, 462-470.	1.7	18
112	The application of â€˜omicsâ€™ to pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 108-120.	5.4	18
113	miR-150-PTPMT1-cardiolipin signaling in pulmonary arterial hypertension. Molecular Therapy - Nucleic Acids, 2021, 23, 142-153.	5.1	18
114	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. Chest, 2021, 160, 1442-1458.	0.8	17
115	Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clinical Science, 2002, 102, 253.	4.3	16
116	Advancing Clinical Trial Design in Pulmonary Hypertension. Pulmonary Circulation, 2013, 3, 217-225.	1.7	16
117	Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovascular Research, 2017, 113, 276-287.	3.8	16
118	The pathophysiological role of novel pulmonary arterial hypertension geneSOX17. European Respiratory Journal, 2021, 58, 2004172.	6.7	16
119	Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma.. Clinical Chemistry, 1989, 35, 953-957.	3.2	15
120	The regulation of pulmonary vascular tone. British Journal of Clinical Pharmacology, 1996, 42, 127-131.	2.4	15
121	Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. American Journal of Physiology - Renal Physiology, 1991, 260, F602-F607.	2.7	14
122	3â€²-Deoxy-3â€²-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circulation: Cardiovascular Imaging, 2018, 11, e007402.	2.6	14
123	Urinary guanosine 3â€²: 5â€²-cyclic monophosphate but not tissue kallikrein follows the plasma atrial natriuretic factor response to acute volume expansion with saline. Clinical Science, 1988, 75, 489-494.	4.3	13
124	Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and Câ€ANP receptor ligand in the rat. British Journal of Pharmacology, 1992, 107, 50-57.	5.4	13
125	A gene for primary pulmonary hypertension. Lancet, The, 2000, 356, 1207-1208.	13.7	13
126	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 348-355.	0.6	13

#	Article	IF	Citations
127	Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 668-676.	1.2	13
128	NHLBI-CMREF Workshop Report on Pulmonary Vascular DiseaseÂClassification. Journal of the American College of Cardiology, 2021, 77, 2040-2052.	2.8	13
129	Captopril reduces the renal response to intravenous atrial natriuretic peptide in normotensives. Journal of Human Hypertension, 1987, 1, 47-51.	2.2	12
130	Genetic and environmental determinants of diastolic heart function. , 2022, 1, 361-371.		12
131	Identification of renal natriuretic peptide receptor subpopulations by use of the nonâ€peptide antagonist, HSâ€142â€1. British Journal of Pharmacology, 1994, 113, 931-939.	5.4	11
132	Downregulation of natriuretic peptide C-receptor protein in the hypertrophied ventricle of the aortovenocaval fistula rat. Cardiovascular Research, 1997, 36, 363-371.	3.8	11
133	Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat. Cardiovascular Research, 1995, 29, 768-74.	3.8	11
134	The effect of propranolol on circulating thyroid hormone measurements in thyrotoxic and euthyroid subjects. European Journal of Endocrinology, 1985, 108, 351-355.	3.7	10
135	Effect of propranolol on thyroid homeostasis of healthy volunteers.. Postgraduate Medical Journal, 1985, 61, 391-394.	1.8	9
136	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 81-93.	5.6	9
137	Hypotension induced by intravascular administration of nerve growth factor in the rat. Clinical Science, 1991, 80, 565-569.	4.3	8
138	Pulmonary Hypertension: Biomarkers. Handbook of Experimental Pharmacology, 2013, , 77-103.	1.8	7
139	Atrial Natriuretic Factor. Annals of Clinical Biochemistry, 1989, 26, 115-118.	1.6	6
140	Carbidopa Does Not Affect the Renal Response to Atrial Natriuretic Factor in Man. Clinical Science, 1989, 77, 281-285.	4.3	6
141	Effect of endopeptidaseâ€24.11 inhibition and of atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat. British Journal of Pharmacology, 1993, 110, 350-354.	5.4	6
142	Renal effects of concurrent Eâ€24.11 and ACE inhibition in the aortoâ€venocaval fistula rat. British Journal of Pharmacology, 1996, 119, 943-948.	5.4	6
143	Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease. Biochemical Society Transactions, 1993, 21, 673-678.	3.4	5
144	Treating acute myocardial infarction: something in the wind?. Lancet, The, 2007, 370, 1461-1462.	13.7	5

#	Article	IF	Citations
145	New Therapeutic Approaches in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2390-2392.	1.6	5
146	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and singleâ€arm efficacy. Pulmonary Circulation, 2021, 11, 1-12.	1.7	5
147	Beta-adrenoceptor blocking drugs and the elderly. Journal of the Royal College of Physicians of London, 1984, 18, 42-5.	0.2	5
148	Meta-iodobenzylguanidine (MIBG) scanning in the diagnosis of phaeochromocytoma. Journal of Human Hypertension, 1993, 7, 353-6.	2.2	5
149	A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension. ERJ Open Research, 2022, 8, 00009-2022.	2.6	5
150	Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function. American Journal of Physiology - Renal Physiology, 1992, 262, F161-F167.	2.7	4
151	Genetic and molecular mechanisms of pulmonary hypertension. Clinical Medicine, 2001, 1, 138-145.	1.9	4
152	Update in Pulmonary Vascular Diseases 2012. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 23-28.	5.6	4
153	Apoptosis Signal-Regulating Kinase 1 Inhibition in Pulmonary Hypertension. Too Much to ASK?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 286-288.	5.6	4
154	DRUG REACTIONS AND THE POOR METABOLISER. Lancet, The, 1983, 322, 110.	13.7	3
155	A placebo controlled comparison of the effects of pirenzepine and amitriptyline on the tyramine pressor test in healthy volunteers.. British Journal of Clinical Pharmacology, 1985, 19, 829-831.	2.4	3
156	A comparison of the effects of the selective peripheralÎ± 1-blocker terazosin with the selectiveÎ² 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension. Clinical Autonomic Research, 1992, 2, 373-381.	2.5	3
157	Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension. Genes, 2020, 11, 1247.	2.4	3
158	Personalized Medicine for Pulmonary Hypertension:. Clinics in Chest Medicine, 2021, 42, 207-216.	2.1	3
159	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. Communications Biology, 2021, 4, 1002.	4.4	3
160	Side effects of benoxaprofen. BMJ: British Medical Journal, 1982, 284, 1782-1783.	2.3	3
161	Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma. Clinical Chemistry, 1989, 35, 953-7.	3.2	3
162	Sodium transport across erythrocyte membranes in diabetes mellitus. Diabetes Research, 1986, 3, 407-10.	0.1	3

#	Article	IF	Citations
163	Raised concentrations of plasma atrial natriuretic peptides in cardiac transplant recipients.. BMJ: British Medical Journal, 1987, 294, 122-122.	2.3	2
164	Response to Letter Regarding Article, â€œCirculating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertensionâ€. Circulation, 2009, 119, .	1.6	2
165	Pulmonary hypertension: Proteins in the blood. Global Cardiology Science & Practice, 2020, 2020, e202007.	0.4	2
166	Metabolomic Insights in Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 103-109.	0.1	2
167	Developments in therapeutics for pulmonary arterial hypertension. Minerva Cardioangiologica, 2002, 50, 175-87.	1.2	2
168	Bosentan. American Journal of Cardiovascular Drugs, 2002, 2, 343.	2.2	1
169	Prof. Almaz A. Aldashev (1953â€“2016). European Respiratory Journal, 2016, 48, 990-991.	6.7	1
170	Editorial: Pulmonary Hypertension: Mechanisms and Management, History and Future. Frontiers in Medicine, 2020, 7, 125.	2.6	1
171	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. European Respiratory Journal, 2020, 56, 1902334.	6.7	1
172	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. , 2011, , 1477-1485.		1
173	Alternative mechanisms for atriopeptin prohormone processing by isolated perfused rat hearts. Journal of Pharmacology and Experimental Therapeutics, 1990, 254, 228-35.	2.5	1
174	TEST FOR CIRCULATING Na+-K+ ATPase INHIBITORS. Lancet, The, 1983, 321, 1219.	13.7	0
175	AMIODARONE AND PLASMA DIGOXIN LEVELS. Lancet, The, 1984, 323, 1180.	13.7	0
176	Bosentan: profile report. Drugs and Therapy Perspectives, 2003, 19, 5-6.	0.6	0
177	S98 Ventilatory efficiency in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: physiological differences and implications for disease-specific end-points. Thorax, 2010, 65, A45-A46.	5.6	0
178	Pulmonary Hypertension: The Value of Experimental Medicine in New Drug Development. Pulmonary Circulation, 2014, 4, 149-150.	1.7	0
179	TORward a Molecular Convergence Point in Pulmonary Arterial Hypertension WithÂmTOR. JACC Basic To Translational Science, 2018, 3, 763-765.	4.1	0
180	Pulmonary hypertension with 2020 vision. British Journal of Pharmacology, 2021, 178, 3-5.	5.4	0

#	Article	IF	Citations
181	Abstract 202: The Role of Neutrophil Extracellular Traps in the Pathogenesis of Pulmonary Hypertension.. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
182	Abstract 230: Protein Farnesylation Inhibitor Tipifarnib Prevents Development of Chronic Hypoxia-induced Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0
183	Dissociation of changes in sodium transport in erythrocytes from changes in blood pressure. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1985, 3, S21-3.	0.1	0
184	Tetrahydrobiopterin And Pulmonary Hypertension. , 2007, , 69-86.		0
185	Sildenafil And Hypoxic Pulmonary Hypertension. , 2007, , 133-143.		0